# US 8,278,498 B2 · Method for producing immortalised antibodies-secreting cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,498 B2
- Document ID: US8278498B2
- Status: Granted
- Kind: B2
- Application number: 10/511,515
- Filed: 2003-04-16
- Published: 2007-06-07
- Granted: 2012-10-02
- Earliest claimed: 2002-04-17
- Assignees: Granta Biotechnology Limited
- Inventors: Jason Peter Brown
- Web page: https://patentgrep.com/patent/US8278498B2

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- C07K 14/82: Translation products from oncogenes
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/85: for animal cells
- A01K 2207/15: Humanized animals
- A01K 2217/00: Genetically modified animals
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/20: Animal model comprising regulated expression system
- A01K 2227/105: Murine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- A01K 2267/03: Animal model, e.g. for test or diseases
- C12N 2510/04: Immortalised cells
- C12N 2517/02: Cells from transgenic animals
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N 2830/15: chimeric enhancer/promoter combination
- Y02A 20/402: River restoration
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method for producing immortalized antibody-secreting cells, comprising: (a) providing a transgenic animal having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalized state in the absence of a stimulus and are capable of changing to an immortalized state by means of the transgene or transgenes upon exposure of the cells to the stimulus; (b) extracting the antibody-secreting cells from the animal; and (c) exposing the antibody-secreting cells to the stimulus, thereby immortalizing the antibody secreting cells by means of the transgene or transgenes.

## Claims

### Claim 1

A method for producing immortalised antibody-secreting cells, comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus;
(b) extracting the antibody-secreting cells from the mouse; and
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes.

### Claim 2 (depends on 1)

A method for producing antibodies, comprising producing immortalised antibody-secreting cells by a method as defined in claim 1, and collecting antibodies from the cells.

### Claim 3

A method for preparing a clonal population of immortalised cells which produce a monoclonal antibody, comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus;
(b) extracting the antibody-secreting cells from the mouse;
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes;
(d) selecting an immortalised antibody-secreting cell which produces the antibody, and
(e) preparing the clonal population of immortalised cells from the immortalised antibody-secreting cell.

### Claim 4 (depends on 1)

A method according to claim 1, wherein expression of a transgene in the antibody-secreting cells is under the control of an inducible promoter, and the stimulus is capable of regulating activity of the promoter and transgene expression.

### Claim 5 (depends on 4)

A method according to claim 4, wherein the stimulus promotes promoter activity and transgene expression.

### Claim 6 (depends on 4)

A method according to claim 4, wherein the stimulus inhibits promoter activity and transgene expression.

### Claim 7 (depends on 1)

A method according to claim 1, wherein a product of a transgene in the antibody-secreting cells promotes immortalisation in the presence of the stimulus, and does not promote immortalisation in the absence of the stimulus.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the transgene is an oncogene.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the oncogene is a gene for the large T antigen.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the transgenic mouse is an immortomouse.

### Claim 11 (depends on 1)

A method according to claim 1, wherein a product of a transgene in the antibody-secreting cells inhibits immortalisation in the absence of the stimulus, and does not inhibit immortalisation in the presence of the stimulus.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the transgene is a tumour suppressor gene.

### Claim 13 (depends on 1)

A method according to claim 1, wherein a product of a transgene in the antibody-secreting cells inhibits a tumour suppressor function in the cells.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the transgene is mdm2.

### Claim 15 (depends on 13)

A method according to claim 13, wherein the transgene comprises cre recombinase, the tumour suppressor function results from a tumour suppressor gene, and the tumour suppressor gene, or a functional part thereof, is flanked with loxp sites.

### Claim 16 (depends on 13)

A method according to claim 13, wherein a product of the transgene comprises an antisense RNA or ribozyme RNA which is capable of inhibiting expression of a tumour suppressor gene.

### Claim 17 (depends on 12)

A method according to claim 12, wherein the tumour suppressor gene comprises p53.

### Claim 18 (depends on 8)

A method according to claim 8, wherein the oncogene comprises myc, abl, bcl-2, v-rel, ras, papillomavirus E6 protein, papillomavirus E7 protein, adenovirus EIA, PIM1, RhoH/TTF or PAX5.

### Claim 19 (depends on 1)

A method according to claim 1, wherein the transgenic mouse comprises antibody-secreting cells in which a tumour suppressor gene has been deleted.

### Claim 20 (depends on 1)

A method according to claim 1, wherein the method comprises the further step of immunising the transgenic mouse with an antigen before step (b).

### Claim 21 (depends on 20)

A method according to claim 20, further comprising selecting an antibody-secreting cell which produces an antibody which recognises the antigen.

### Claim 22 (depends on 3)

A method according to claim 3, wherein step (d) comprises fluorescence activated cell sorting.

### Claim 23 (depends on 1)

A method according to claim 1, wherein the transgenic mouse is not immunised.

### Claim 24 (depends on 1)

A method according to claim 1, wherein the stimulus comprises a temperature change.

### Claim 25 (depends on 1)

A method according to claim 1, wherein the stimulus comprises a chemical stimulus.

### Claim 26 (depends on 1)

A method according to claim 1, wherein the antibody-secreting cells are B lymphocytes.

### Claim 27 (depends on 1)

A method according to claim 1, wherein the antibody is a humanised antibody.

### Claim 28 (depends on 1)

A method according to claim 1, comprising a further step of storing the antibody-secreting cells at a temperature of 0° C. or below, after extracting the antibody-secreting cells from the mouse, and before or after exposing the antibody-secreting cells to the stimulus.

### Claim 29 (depends on 3)

A method for producing a monoclonal antibody, comprising producing a population of immortalised cells by a method as defined in claim 3, and producing the monoclonal antibody from the population of immortalised cells.

### Claim 30 (depends on 13)

A method according to claim 13, wherein the tumor suppressor function comprises p53.

### Claim 31

A method for producing antibodies comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus;
(b) extracting the antibody-secreting cells from the mouse;
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes; and
(d) collecting antibodies from the antibody-secreting cells, wherein the antibody-secreting cells are B lymphocytes.

### Claim 32

A method for producing antibodies comprising:
(a) providing a germline transgenic mouse having antibody-secreting cells capable of expressing one or more transgenes, wherein the antibody-secreting cells are in a non-immortalised state in the absence of a stimulus and change to an immortalised state by means of the transgene or transgenes upon exposure of the cells to the stimulus, which mouse has been immunised with an antigen;
(b) extracting the antibody-secreting cells from the mouse;
(c) exposing the antibody-secreting cells to the stimulus, thereby immortalising the antibody-secreting cells by means of the transgene or transgenes; and
(d) collecting antibodies from the antibody-secreting cells.
